Site KR82003

Seoul 135-710

2 studies enrolling now · 16 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Solid Tumors, Allogeneic, Hematopoietic Cell Transplant (HCT), Bladder Cancer, Cytomegalovirus (CMV)-Positive Recipients, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma, Metastatic Hormone Sensitive Prostate Cancer

Studies at this site

• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder — Recruiting now
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer — Recruiting now
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study — Recruiting now
• A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). — Running, not enrolling
• A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer — Running, not enrolling
• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Running, not enrolling
• A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. — Running, not enrolling
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) — Completed
• Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy — Completed
• A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Completed
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) — Completed
• A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide — Completed
• A Study of ASP1951 in Subjects With Advanced Solid Tumors — Stopped early
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors — Completed
• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder — Completed
• A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) — Completed